Company intelligence / Profile preview
Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Jinhua, Zhejiang, Chinaen.zjjfpharm.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
The company has multiple approved drugs including Roxadustat (approved in China in 2018), Empagliflozin/metformin Hydrochloride (approved in EU in 2015), and others. Recently, their Esomeprazole Magnesium Enteric-coated Dry Suspension won a bid for National Centralized Drug Procurement.
- Therapeutic areas
- OncologyEndocrinologyPsychiatryGastroenterologyCardiovascularNephrologyInfectious Diseases
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Collaborations with German research institutions
Beyond the preview
Go deeper on Zhejiang Jianfeng Pharmaceutical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Jianfeng Pharmaceutical Co., Ltd..